{"id":"tazorac-cream","_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Tazorac Cream","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:08:56.344291+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:09:01.378909+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tazorac Cream","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:09:01.629585+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108947/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:09:02.499988+00:00"}},"_dailymed":null,"_scrapedAt":"2026-03-27T23:38:27.688Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:09:04.106089+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT00469755","phase":"PHASE4","title":"Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2006-02","conditions":"Acne Vulgaris","enrollment":302},{"nctId":"NCT03599193","phase":"PHASE2","title":"A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2017-10-04","conditions":"Acne Vulgaris","enrollment":58},{"nctId":"NCT00489086","phase":"PHASE2","title":"Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face","status":"COMPLETED","sponsor":"UCSF Benioff Children's Hospital Oakland","startDate":"2004-07","conditions":"Neoplastic Syndrome","enrollment":36},{"nctId":"NCT02938494","phase":"PHASE2","title":"Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2015-11","conditions":"Acne Vulgaris","enrollment":210},{"nctId":"NCT02785159","phase":"PHASE2","title":"Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2016-02","conditions":"Psoriasis","enrollment":152},{"nctId":"NCT03341910","phase":"PHASE2","title":"A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2017-08-21","conditions":"Acne Vulgaris","enrollment":155},{"nctId":"NCT00440024","phase":"NA","title":"The Effect Of A Controlled Daily Skin Care Regimen On Retinoic Acid Tolerance","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2007-02","conditions":"Sun-Damaged Skin, Retinoid Intolerance","enrollment":40},{"nctId":"NCT02886702","phase":"PHASE3","title":"A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Fougera Pharmaceuticals Inc.","startDate":"2016-09-19","conditions":"Plaque Psoriasis","enrollment":855},{"nctId":"NCT02886715","phase":"PHASE3","title":"A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Fougera Pharmaceuticals Inc.","startDate":"2016-09-21","conditions":"Acne Vulgaris","enrollment":1110},{"nctId":"NCT02849873","phase":"PHASE1","title":"Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2016-06","conditions":"Acne","enrollment":48},{"nctId":"NCT03058744","phase":"PHASE1","title":"Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2015-04","conditions":"Psoriasis","enrollment":94},{"nctId":"NCT02411955","phase":"PHASE1","title":"A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2014-06","conditions":"Acne Vulgaris","enrollment":1077},{"nctId":"NCT01016977","phase":"PHASE4","title":"A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-10","conditions":"Acne Vulgaris","enrollment":40},{"nctId":"NCT02160678","phase":"PHASE3","title":"Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"G & W Laboratories Inc.","startDate":"2014-05","conditions":"Acne Vulgaris","enrollment":1741},{"nctId":"NCT02160665","phase":"PHASE3","title":"Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"G & W Laboratories Inc.","startDate":"2014-05","conditions":"Plaque Psoriasis","enrollment":866},{"nctId":"NCT00783965","phase":"PHASE2","title":"Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back","status":"COMPLETED","sponsor":"UCSF Benioff Children's Hospital Oakland","startDate":"2004-07","conditions":"Skin Carcinoma","enrollment":34},{"nctId":"NCT02525822","phase":"PHASE2","title":"Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris","status":"UNKNOWN","sponsor":"Valeant Pharmaceuticals","startDate":"2015-09","conditions":"Acne Vulgaris","enrollment":210},{"nctId":"NCT02218034","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-08","conditions":"Acne Vulgaris","enrollment":78},{"nctId":"NCT00829049","phase":"PHASE4","title":"Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris","status":"TERMINATED","sponsor":"Allergan","startDate":"2007-10","conditions":"Acne Vulgaris","enrollment":165},{"nctId":"NCT00834210","phase":"PHASE4","title":"Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-12","conditions":"Acne Vulgaris","enrollment":171},{"nctId":"NCT00779896","phase":"PHASE1, PHASE2","title":"Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study","status":"UNKNOWN","sponsor":"McGill University","startDate":"2008-10","conditions":"Cutaneous T-Cell Lymphoma","enrollment":15}],"_emaApprovals":[],"_faersSignals":[{"count":7,"reaction":"ERYTHEMA"},{"count":4,"reaction":"PREGNANCY"},{"count":4,"reaction":"SKIN EXFOLIATION"},{"count":4,"reaction":"SKIN IRRITATION"},{"count":3,"reaction":"ACNE"},{"count":3,"reaction":"APPLICATION SITE ERYTHEMA"},{"count":3,"reaction":"DRY SKIN"},{"count":3,"reaction":"OFF LABEL USE"},{"count":3,"reaction":"PRURITUS"},{"count":2,"reaction":"FEELING HOT"}],"crossReferences":{"chemblId":"CHEMBL2108947"},"_approvalHistory":[],"publicationCount":116,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tazorac","tazarotene","Tazarotene","Taz"],"phase":"marketed","status":"active","brandName":"Tazorac Cream","genericName":"Tazorac Cream","companyName":"Bausch Health Americas, Inc.","companyId":"bausch-health-americas-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:09:04.106089+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}